[go: up one dir, main page]

NO20091976L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20091976L
NO20091976L NO20091976A NO20091976A NO20091976L NO 20091976 L NO20091976 L NO 20091976L NO 20091976 A NO20091976 A NO 20091976A NO 20091976 A NO20091976 A NO 20091976A NO 20091976 L NO20091976 L NO 20091976L
Authority
NO
Norway
Prior art keywords
new connections
connections
new
applications
methods
Prior art date
Application number
NO20091976A
Other languages
English (en)
Inventor
Beat Schmitz
Gottfried Sedelmeier
Olivier Loiseleur
Daniel Kaufmann
Stephan Abel
Hans Michael Buerger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20091976L publication Critical patent/NO20091976L/no
Application filed by Novartis Ag filed Critical Novartis Ag

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører nye forbindelser, fremgangsmåterog anvendelser.
NO20091976A 2002-02-07 2009-05-20 Nye forbindelser NO20091976L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202873.6A GB0202873D0 (en) 2002-02-07 2002-02-07 Organic compounds
PCT/EP2003/001188 WO2003066613A1 (en) 2002-02-07 2003-02-06 N-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
NO20091976L true NO20091976L (no) 2004-11-05

Family

ID=9930607

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20043685A NO327366B1 (no) 2002-02-07 2004-09-03 Amider og fremgangsmåter for fremstilling derav
NO20091976A NO20091976L (no) 2002-02-07 2009-05-20 Nye forbindelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20043685A NO327366B1 (no) 2002-02-07 2004-09-03 Amider og fremgangsmåter for fremstilling derav

Country Status (25)

Country Link
US (8) US7456283B2 (no)
EP (2) EP1474408B1 (no)
JP (2) JP4653954B2 (no)
KR (1) KR101027044B1 (no)
CN (2) CN100347162C (no)
AU (1) AU2003244444B2 (no)
BR (2) BR0307529A (no)
CA (2) CA2737565C (no)
CO (1) CO5601018A2 (no)
CY (2) CY1112938T1 (no)
DK (2) DK1474408T3 (no)
EC (2) ECSP045220A (no)
ES (2) ES2384872T3 (no)
GB (1) GB0202873D0 (no)
IL (3) IL163158A (no)
MX (1) MXPA04007642A (no)
NO (2) NO327366B1 (no)
NZ (3) NZ554430A (no)
PL (1) PL209475B1 (no)
PT (2) PT2248807E (no)
RU (2) RU2370493C2 (no)
SG (1) SG160195A1 (no)
SI (2) SI2248807T1 (no)
WO (1) WO2003066613A1 (no)
ZA (1) ZA200405970B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
CN1805748B (zh) * 2003-06-13 2010-05-26 诺瓦提斯公司 作为raf激酶抑制剂的2-氨基嘧啶衍生物
PE20051096A1 (es) 2004-02-04 2006-01-23 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
CN101951889A (zh) * 2006-09-01 2011-01-19 特瓦制药工业有限公司 伊马替尼组合物
AU2007299764B2 (en) 2006-09-22 2011-10-13 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors
MX2008008447A (es) * 2006-10-26 2008-09-15 Sicor Inc Proceso para la preparacion de imatinib.
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
BRPI0718812A2 (pt) * 2006-11-16 2013-12-03 Italiana Sint Spa Processo para a preparação de imatinib e intermediários deste
CN100451015C (zh) * 2007-02-14 2009-01-14 杭州盛美医药科技开发有限公司 一种伊马替尼的制备方法
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
CN101497601B (zh) * 2008-01-29 2012-11-07 福建南方制药股份有限公司 伊马替尼的合成方法
PL215042B1 (pl) * 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania imatinibu
KR20100021321A (ko) * 2008-08-14 2010-02-24 일양약품주식회사 Ν-페닐-2-피리미딘-아민 유도체의 제조방법
WO2010065433A1 (en) 2008-12-01 2010-06-10 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
US20100330130A1 (en) 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
CN101654416B (zh) * 2009-09-16 2013-06-05 成都神黄医药科技开发有限公司 N-[3-硝基-4-甲基-苯基]-4-醛基-苯甲酰胺及其制备方法以及其衍生物的制备方法
EP2509973A1 (en) 2009-12-10 2012-10-17 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
US8609842B2 (en) 2010-04-23 2013-12-17 Fujian South Pharmaceutical Co., Ltd. Method for synthesizing Imatinib
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
TR201007005A2 (tr) 2010-08-23 2011-09-21 Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. İmatinib baz üretim yöntemi
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
PH12014500897A1 (en) 2011-10-28 2019-10-07 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
BR112015000349A2 (pt) 2012-07-11 2017-06-27 Novartis Ag método de tratamento de tumores estromais gastrointestinais
CN102827144A (zh) * 2012-09-05 2012-12-19 湖南欧亚生物有限公司 一种伊马替尼的制备方法
RU2537398C1 (ru) * 2013-08-20 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный технологический университет" (СибГТУ) Гексазамещенные пара-аминофенолы с ариламидными группами в 2,6-положениях по отношению к гидроксилу
CN103588754B (zh) * 2013-11-04 2015-05-27 遵义医学院 伊马替尼的制备方法
CN109803659A (zh) 2016-10-17 2019-05-24 德尔塔菲制药股份有限公司 用于治疗或缓解慢性髓性白血病的药物组合物
EP3539138B1 (en) 2016-11-11 2021-05-19 Curium US LLC Processes for generating germanium-68 with reduced volatiles
EP3333162A1 (en) 2016-12-12 2018-06-13 Silesian Catalysts sp. z o.o. Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
PL3697785T3 (pl) 2017-10-18 2023-08-07 Jubilant Epipad LLC Związki imidazopirydynowe jako inhibitory pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
DK3704120T3 (da) 2017-11-24 2024-05-21 Jubilant Episcribe Llc Heterocykliske forbindelser som prmt5-inhibitorer
CN108164505B (zh) * 2018-01-16 2020-11-03 扬州大学 一种伊马替尼的合成方法
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE531480C (de) 1929-07-03 1931-08-10 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Aryliden einer unsymmetrischen o-Xylenolcarbonsaeure
US2808433A (en) * 1953-08-21 1957-10-01 Du Pont Benzene dicarboxylic acid derivatives
GB862127A (en) 1958-07-04 1961-03-01 Ici Ltd Derivatives of 2-hydroxy-3-naphthanilide
US3505433A (en) * 1965-03-08 1970-04-07 Hooker Chemical Corp 2-haloperfluoro-1-cycloalken-1-ylphosphoryl compounds
US3505389A (en) * 1966-08-18 1970-04-07 Hooker Chemical Corp 4-amino-2,3,5,6-tetrachlorobenzoic acid and derivatives thereof
US3505398A (en) 1966-09-22 1970-04-07 Standard Oil Co Terephthalic acid crystallization
US3763234A (en) * 1970-12-03 1973-10-02 Halcon International Inc Preparation of amides
JPS4987761U (no) 1972-11-17 1974-07-30
JPS563375B2 (no) * 1972-12-25 1981-01-24
JPS5720923B2 (no) * 1974-04-02 1982-05-04
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
JPS5665804A (en) * 1979-11-01 1981-06-03 Ishihara Sangyo Kaisha Ltd Control agent against injurious organism
DE3305755A1 (de) * 1983-02-19 1984-08-23 Gödecke AG, 1000 Berlin N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems
US4623486A (en) 1985-05-29 1986-11-18 Pfizer Inc. [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
JP2894804B2 (ja) * 1989-07-19 1999-05-24 武田薬品工業株式会社 ２―アミノ―５―メチルベンゾフェノン類及びその製造法
JPH03130252U (no) 1990-04-11 1991-12-27
FR2664895B1 (fr) * 1990-07-20 1992-10-30 Theramex Laboratoire Nouveaux derives de la 6-methyl 19-nor progesterone, substitues en 3 et leur procede d'obtention.
DE4110483A1 (de) 1991-03-30 1992-10-01 Bayer Ag Substituierte salicylamide, mittel gegen pflanzenkrankheiten
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2689925B1 (fr) 1992-04-08 1994-05-27 Valeo Securite Habitacle Dispositif de verrouillage d'une serrure dans son support.
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DE4428380A1 (de) * 1994-08-11 1996-02-15 Bayer Ag 4-Trifluormethylbenzamide
IL117440A0 (en) * 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process
JPH0987761A (ja) 1995-09-22 1997-03-31 Nikko Kinzoku Kk 銅転炉スラグからの銅の回収方法
JP3130252B2 (ja) 1996-07-12 2001-01-31 小糸工業株式会社 座席のヘッドレスト装置
ES2214707T3 (es) * 1997-06-30 2004-09-16 Targacept, Inc. Derivados de 3-piridil-1-azabicicloalcano para la prevencion y tratamiento de trastornos del snc.
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO1999059959A1 (en) * 1998-05-15 1999-11-25 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
IL141979A0 (en) 1998-09-25 2002-03-10 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9924092D0 (en) * 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
EP2248807B1 (en) 2013-07-03
GB0202873D0 (en) 2002-03-27
CA2474738C (en) 2011-10-04
CY1114351T1 (el) 2016-08-31
IL189658A (en) 2011-05-31
BR0307529A (pt) 2004-12-21
US20150018552A1 (en) 2015-01-15
US9573928B2 (en) 2017-02-21
AU2003244444B9 (en) 2003-09-02
ES2384872T3 (es) 2012-07-13
NZ554430A (en) 2008-08-29
ECSP095220A (es) 2009-08-28
PL371197A1 (en) 2005-06-13
JP4653954B2 (ja) 2011-03-16
ZA200405970B (en) 2006-05-31
JP2010138194A (ja) 2010-06-24
BRPI0307529B1 (pt) 2018-01-30
US20120226039A1 (en) 2012-09-06
US7579467B2 (en) 2009-08-25
AU2003244444A1 (en) 2003-09-02
ES2425980T3 (es) 2013-10-18
RU2370493C2 (ru) 2009-10-20
RU2007148217A (ru) 2009-07-10
KR101027044B1 (ko) 2011-04-11
IL189657A (en) 2010-12-30
PT1474408E (pt) 2012-07-25
AU2003244444B2 (en) 2007-08-09
NZ569731A (en) 2009-11-27
RU2004126941A (ru) 2005-10-10
US20060142580A1 (en) 2006-06-29
SI1474408T1 (sl) 2012-07-31
US20090137805A1 (en) 2009-05-28
CY1112938T1 (el) 2016-04-13
NO327366B1 (no) 2009-06-15
US20070293683A1 (en) 2007-12-20
US20070293504A1 (en) 2007-12-20
MXPA04007642A (es) 2004-11-10
JP2005528340A (ja) 2005-09-22
SG160195A1 (en) 2010-04-29
CA2737565A1 (en) 2003-08-14
EP2248807A1 (en) 2010-11-10
US20070293673A1 (en) 2007-12-20
DK2248807T3 (da) 2013-08-26
NO20043685L (no) 2004-11-05
HK1145322A1 (en) 2011-04-15
CA2737565C (en) 2013-04-09
PL209475B1 (pl) 2011-09-30
EP1474408B1 (en) 2012-05-23
IL189657A0 (en) 2008-06-05
SI2248807T1 (sl) 2013-10-30
CN1630648A (zh) 2005-06-22
EP1474408A1 (en) 2004-11-10
ECSP045220A (es) 2004-09-28
KR20040081154A (ko) 2004-09-20
NZ534315A (en) 2007-06-29
CN101016262A (zh) 2007-08-15
PT2248807E (pt) 2013-09-02
US7825247B2 (en) 2010-11-02
CN100347162C (zh) 2007-11-07
HK1070893A1 (en) 2005-06-30
IL163158A (en) 2010-11-30
WO2003066613A1 (en) 2003-08-14
CO5601018A2 (es) 2006-01-31
DK1474408T3 (da) 2012-06-25
US20070293672A1 (en) 2007-12-20
US7816359B2 (en) 2010-10-19
US7456283B2 (en) 2008-11-25
CA2474738A1 (en) 2003-08-14
IL189658A0 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
NO20091976L (no) Nye forbindelser
BRPI0414599A (pt) pirrol-indóis substituìdos
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
DE60228071D1 (de) Spiropyrazol-verbindungen
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
NO20041493L (no) Kjemiske forbindelser.
DK1644348T3 (da) Epoxy-afsluttede polythioethere, Epoxy-afsluttede polythioethere
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
UY3450Q (es) Botella
ATE445386T1 (de) Polymerische parfümpartikel
SE0301653D0 (sv) Novel compounds
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
NO20044448L (no) Nye forbindelser
NO20044898L (no) Nye etonogestrel estere
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
PL380950A1 (pl) Pewne związki amionoalkiloglukozaminidofosforanowe i ich zastosowanie
DK1628989T3 (da) Hidtil ukendte, 14- og 15-leddet ring-forbindelser
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
DE50310579D1 (de) Furancarboxamide
DE502004003470D1 (de) Wasserlösliche, fluoreszierende perylentetracarbonsäure bisimide
ATE483714T1 (de) Podophyllotoxine als antiproliferative mittel
BRPI0417205A (pt) composições farmacêuticas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application